Manatuck Hill Partners Upped Mgp Ingredients New (MGPI) Position; Dentsply Sirona (XRAY) Shorts Lowered By 3.91%

December 16, 2017 - By Adrian Erickson

Dentsply Sirona Incorporated (NASDAQ:XRAY) had a decrease of 3.91% in short interest. XRAY’s SI was 8.11M shares in December as released by FINRA. Its down 3.91% from 8.44M shares previously. With 1.91 million avg volume, 4 days are for Dentsply Sirona Incorporated (NASDAQ:XRAY)’s short sellers to cover XRAY’s short positions. The SI to Dentsply Sirona Incorporated’s float is 3.74%. The stock increased 1.26% or $0.83 during the last trading session, reaching $66.48. About 1.75M shares traded. DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has risen 2.17% since December 16, 2016 and is uptrending. It has underperformed by 14.53% the S&P500.

Manatuck Hill Partners Llc increased Mgp Ingredients Inc New (MGPI) stake by 11.59% reported in 2017Q2 SEC filing. Manatuck Hill Partners Llc acquired 20,000 shares as Mgp Ingredients Inc New (MGPI)’s stock rose 22.02%. The Manatuck Hill Partners Llc holds 192,600 shares with $9.86M value, up from 172,600 last quarter. Mgp Ingredients Inc New now has $1.22 billion valuation. The stock decreased 1.21% or $0.89 during the last trading session, reaching $72.96. About 201,605 shares traded or 85.51% up from the average. MGP Ingredients, Inc. (NASDAQ:MGPI) has risen 102.52% since December 16, 2016 and is uptrending. It has outperformed by 85.82% the S&P500.

Among 19 analysts covering Dentsply International (NASDAQ:XRAY), 14 have Buy rating, 1 Sell and 4 Hold. Therefore 74% are positive. Dentsply International had 47 analyst reports since August 3, 2015 according to SRatingsIntel. On Monday, September 14 the stock rating was upgraded by Morgan Stanley to “Overweight”. The firm has “Hold” rating by H.C. Wainwright given on Thursday, December 7. Stifel Nicolaus upgraded the stock to “Buy” rating in Tuesday, February 14 report. As per Monday, November 6, the company rating was upgraded by Barrington Research. The rating was initiated by Deutsche Bank with “Buy” on Friday, December 8. The stock of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) earned “Sell” rating by Goldman Sachs on Tuesday, May 23. Northcoast upgraded DENTSPLY SIRONA Inc. (NASDAQ:XRAY) on Friday, September 18 to “Buy” rating. The stock has “Buy” rating by Stifel Nicolaus on Tuesday, October 17. The firm has “Mkt Perform” rating given on Tuesday, February 21 by Barrington Research. The stock of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) earned “Neutral” rating by UBS on Thursday, February 25.

Investors sentiment increased to Infinity in Q2 2017. Its up Infinity, from 4 in 2017Q1. It is positive, as 1 investors sold DENTSPLY SIRONA Inc. shares while 0 reduced holdings. 0 funds opened positions while 4 raised stakes. 779,672 shares or 121.05% more from 352,708 shares in 2017Q1 were reported. Gemmer Asset Management holds 0.01% or 237 shares in its portfolio. Tirschwell & Loewy Incorporated holds 2.47% or 243,211 shares. Burney has 0.02% invested in DENTSPLY SIRONA Inc. (NASDAQ:XRAY). Cardinal Cap Management accumulated 1.51% or 70,606 shares. West Oak Cap Limited Company reported 22,735 shares. Cibc World Markets reported 49,396 shares.

DENTSPLY SIRONA Inc. designs, develops, makes, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company has market cap of $15.27 billion. It operates through two divisions, Dental and Healthcare Consumables; and Technologies. It currently has negative earnings. The firm provides dental consumable products, including endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprising dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Since August 17, 2017, it had 0 insider purchases, and 4 sales for $2.27 million activity. Another trade for 6,598 shares valued at $396,300 was sold by Seaberg Karen.

Investors sentiment increased to 1.32 in Q2 2017. Its up 0.39, from 0.93 in 2017Q1. It improved, as 24 investors sold MGPI shares while 30 reduced holdings. 7 funds opened positions while 43 raised stakes. 16.10 million shares or 1.62% more from 15.85 million shares in 2017Q1 were reported. Denver Advsr Ltd holds 0.03% of its portfolio in MGP Ingredients, Inc. (NASDAQ:MGPI) for 12,365 shares. Rhumbline Advisers owns 14,322 shares. Bnp Paribas Arbitrage reported 1,629 shares stake. Credit Suisse Ag stated it has 20,468 shares. Stephens Inc Ar reported 0% stake. 7,731 were reported by Stifel Fincl. Northwestern Mutual Wealth Management Company stated it has 0% of its portfolio in MGP Ingredients, Inc. (NASDAQ:MGPI). Legal General Grp Inc Public Ltd Company reported 0% in MGP Ingredients, Inc. (NASDAQ:MGPI). Kennedy Cap Management owns 0.04% invested in MGP Ingredients, Inc. (NASDAQ:MGPI) for 44,887 shares. Schwab Charles Mgmt Inc holds 0% or 62,828 shares in its portfolio. Ameritas Inv Ptnrs Inc, Nebraska-based fund reported 1,083 shares. Raymond James Tru Na reported 0.1% of its portfolio in MGP Ingredients, Inc. (NASDAQ:MGPI). Wells Fargo & Mn invested 0% of its portfolio in MGP Ingredients, Inc. (NASDAQ:MGPI). Skylands Ltd Liability has invested 0.06% of its portfolio in MGP Ingredients, Inc. (NASDAQ:MGPI). State Street holds 0% in MGP Ingredients, Inc. (NASDAQ:MGPI) or 234,916 shares.

Among 3 analysts covering MGP Ingredients (NASDAQ:MGPI), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. MGP Ingredients had 3 analyst reports since May 25, 2016 according to SRatingsIntel. Craig Hallum initiated the stock with “Buy” rating in Wednesday, May 25 report. The company was initiated on Wednesday, February 1 by Sidoti.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: